CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"CrownBio and OcellO believe that the key to improving clinical research success is to utilize more patient-relevant models and assays that can generate reliable efficacy data as early as possible in the drug development process," said Armin Spura, PhD, Chief Executive Officer of CrownBio. "This acquisition brings together the complementary strengths of our two companies, enhancing our in vitro services portfolio and offering customers the ability to better evaluate multiple drug combinations and targets, across a wider range of tumor and cancer types, with improved predictability and clinical relevance moving from in vitro to in vivo phases of drug discovery."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SAN DIEGO -- Businesswire -- Crown Bioscience (CrownBio), a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a privately owned contract research organization located in the Netherlands. Through the acquisition, CrownBio will expand its portfolio of in vitro services, integrating OcellO’s expertise in high content imaging alongside CrownBio’s in vitro and in vivo screens and immunotherapy assessment services. Financial terms are not being disclosed.
“CrownBio and OcellO believe that the key to improving clinical research success is to utilize more patient-relevant models and assays that can generate reliable efficacy data as early as possible in the drug development process,” said Armin Spura, PhD, Chief Executive Officer of CrownBio. “This acquisition brings together the complementary strengths of our two companies, enhancing our in vitro services portfolio and offering customers the ability to better evaluate multiple drug combinations and targets, across a wider range of tumor and cancer types, with improved predictability and clinical relevance moving from in vitro to in vivo phases of drug discovery.”
The acquisition establishes CrownBio as the only global source licensed to offer customers specialized Hubrecht Organoid Technology (HUB) for drug development programs. Under the terms of the agreement, Leo Price, PhD, OcellO’s Chief Executive Officer and Chief Scientific Officer, will join CrownBio as Senior Vice President, In Vitro, to lead the Company’s in vitro business in the US and Europe.
“I am delighted to join CrownBio and help grow the company’s in vitro portfolio,” said Dr. Price. “We will continue our shared heritage of innovation and dedication to customer service to serve complex needs in early-stage cancer drug development. Our combined expertise is particularly suited for disease-relevant large-scale screening, allowing our customers to evaluate multiple drug combinations in a rapid, scientifically rigorous, and cost-effective way.”
About Crown Bioscience Inc. Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and inflammatory disorders. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
About OcellO B.V. OcellO is a leading provider of compound testing services using advanced organotypic human tissue models of cancer, inflammation, and polycystic kidney disease. Automated 3D cell culture technology is combined with high content 3D imaging and analysis in a robust platform that provides scalability without compromising biological complexity. Cancer drug discovery services utilize organoids, PDX- derived tumoroids and patient tumor-derived models representing most solid tumor types and incorporating different components of the immune system.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005619/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Crown Bioscience Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 송도국제캠핑장, 바베큐장 ‘더 팜 송도’ 그랜드 오픈 - 뉴스와이어
- 김명중 사진작가와 프로쉬 ‘22세기 유물전’ 개최 - 뉴스와이어
- 벼룩시장 조사, 직장인 10명 중 9명 ‘고용불안 느낀다’ - 뉴스와이어
- 반스 월드 2, 로블록스에서 새로운 스케이트 챌린지 선보여 - 뉴스와이어
- 해양수산부, 제10회 해양수산 창업콘테스트 개최 - 뉴스와이어
- 평창 여름 행사 ‘시원한 여름, 신나는 여름, 맛있는 여름’ 개최 - 뉴스와이어
- ‘역대 최대 115만여 명 참가’ 제21회 서울국제환경영화제 성공적 마무리 - 뉴스와이어
- HL만도 주차로봇 ‘파키’ 인천국제공항서 발렛파킹 실증 운영 - 뉴스와이어
- 증가하는 청년 자살… 청년이 직접 자살예방 활동을 하는 ‘청년 자살예방 서포터즈 3기’ 출발
- AI 버추얼 아티스트 수비, 디지털 싱글 ‘SUNCREAM’ 콘셉트 포토 공개 - 뉴스와이어